Ardelyx Completes Enrollment In Phase 3 ACCEL Clinical Trial Of IBSRELA
Trial fully enrolled ahead of scheduleTopline data expected in the second half of 2027
Share
Why It Matters
Ardelyx finished signing up all patients for a big medicine test early. Watch for results in late 2027 to see if the drug works.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.